NASDAQ:EYPT - Eyepoint Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.00 +0.05 (+2.56 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$2.00
Today's Range$1.9339 - $2.00
52-Week Range$0.93 - $2.88
Volume182,029 shs
Average Volume290,300 shs
Market Capitalization$105.36 million
P/E Ratio-3.85
Dividend YieldN/A
Beta0.81
Eyepoint Pharmaceuticals logoEyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis. Its lead product candidate is Durasert, (fluocinolone acetonide intravitreal implant), a micro-insert for the treatment of non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's pre-clinical development program focuses on using its core Durasert platform technology to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. It has license agreements with Bausch and Lomb for Retisert product; a license agreement with Alimera for ocular applications of the ILUVIEN device; and a collaboration agreement with Pfizer for the Durasert device delivering latanoprost. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.

Receive EYPT News and Ratings via Email

Sign-up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EYPT
CUSIPN/A
Phone617-926-5000

Debt

Debt-to-Equity Ratio1.57
Current Ratio0.83
Quick Ratio0.83

Price-To-Earnings

Trailing P/E Ratio-3.85
Forward P/E Ratio-4.17
P/E GrowthN/A

Sales & Book Value

Annual Sales$7.54 million
Price / Sales14.33
Cash FlowN/A
Price / CashN/A
Book Value$0.34 per share
Price / Book5.88

Profitability

EPS (Most Recent Fiscal Year)($0.52)
Net Income$-18,480,000.00
Net Margins-843.54%
Return on Equity-246.01%
Return on Assets-103.22%

Miscellaneous

Employees22
Outstanding Shares54,030,000

The Truth About Cryptocurrencies

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Frequently Asked Questions

What is Eyepoint Pharmaceuticals' stock symbol?

Eyepoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."

How were Eyepoint Pharmaceuticals' earnings last quarter?

Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) posted its quarterly earnings results on Tuesday, May, 8th. The company reported ($0.15) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.02. The company had revenue of $0.93 million for the quarter, compared to analyst estimates of $0.69 million. Eyepoint Pharmaceuticals had a negative return on equity of 246.01% and a negative net margin of 843.54%. View Eyepoint Pharmaceuticals' Earnings History.

When is Eyepoint Pharmaceuticals' next earnings date?

Eyepoint Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, September, 10th 2018. View Earnings Estimates for Eyepoint Pharmaceuticals.

What price target have analysts set for EYPT?

4 equities research analysts have issued twelve-month price targets for Eyepoint Pharmaceuticals' shares. Their forecasts range from $3.00 to $10.00. On average, they expect Eyepoint Pharmaceuticals' share price to reach $5.75 in the next year. View Analyst Ratings for Eyepoint Pharmaceuticals.

Are investors shorting Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals saw a decline in short interest during the month of May. As of May 31st, there was short interest totalling 1,354,489 shares, a decline of 28.2% from the May 15th total of 1,885,770 shares. Based on an average daily volume of 392,538 shares, the short-interest ratio is currently 3.5 days. Currently, 3.1% of the shares of the stock are short sold. View Eyepoint Pharmaceuticals' Current Options Chain.

Who are some of Eyepoint Pharmaceuticals' key competitors?

Who are Eyepoint Pharmaceuticals' key executives?

Eyepoint Pharmaceuticals' management team includes the folowing people:
  • Ms. Nancy S. Lurker, Pres, CEO & Director (Age 61)
  • Mr. Leonard S. Ross, VP of Fin., Chief Accounting Officer & Principal Financial Officer (Age 68)
  • Dr. Dario A. Paggiarino M.D., VP & Chief Medical Officer (Age 61)
  • Mr. Marty Nazzaro, Sr. VP of Operations
  • Dr. Anna Kluczewska B.D.Sc., CEO of AION Diagnostics Ltd, Pres of AION Diagnostics Ltd and Director of AION Diagnostics Ltd

Has Eyepoint Pharmaceuticals been receiving favorable news coverage?

Media coverage about EYPT stock has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Eyepoint Pharmaceuticals earned a media sentiment score of 0.06 on Accern's scale. They also gave media stories about the company an impact score of 45.40 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of Eyepoint Pharmaceuticals?

Shares of EYPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eyepoint Pharmaceuticals' stock price today?

One share of EYPT stock can currently be purchased for approximately $2.00.

How big of a company is Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals has a market capitalization of $105.36 million and generates $7.54 million in revenue each year. The company earns $-18,480,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Eyepoint Pharmaceuticals employs 22 workers across the globe.

How can I contact Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The company can be reached via phone at 617-926-5000 or via email at [email protected]


MarketBeat Community Rating for Eyepoint Pharmaceuticals (EYPT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  214 (Vote Outperform)
Underperform Votes:  129 (Vote Underperform)
Total Votes:  343
MarketBeat's community ratings are surveys of what our community members think about Eyepoint Pharmaceuticals and other stocks. Vote "Outperform" if you believe EYPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.